Logo Image

Shambavi Richard, MD

Articles by Shambavi Richard, MD

7 experts are featured in this series

Case Discussion: Choosing Between CAR-T Cell Therapy and BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

ByShambavi Richard, MD,Prashant Kapoor, MD,Mansi Shah, MD,Ridhi Gupta, MD,Cesar Rodriguez, MD,Harsh Parmar, MD,Gurbakhash Kaur, MD

The faculty discuss treatment selection for a fit patient with relapsed/refractory multiple myeloma (R/R MM) who is eligible for both CAR-T cell therapy and BCMA bispecific antibodies and has access to a certified CAR-T treatment center.

7 experts are featured in this series

Case Discussion: Selecting BCMA Bispecific Therapy for a Patient With Relapsed/Refractory Multiple Myeloma and Limited Access to CAR-T

ByShambavi Richard, MD,Prashant Kapoor, MD,Mansi Shah, MD,Ridhi Gupta, MD,Cesar Rodriguez, MD,Harsh Parmar, MD,Gurbakhash Kaur, MD

The faculty discuss the management of a patient with relapsed/refractory multiple myeloma (R/R MM) who has received four prior lines of therapy but faces significant logistical barriers to CAR-T treatment because of limited caregiver support and distance from a cellular therapy center.

7 experts are featured in this series

Debate: Class Effect Versus Meaningful Differences Among BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

ByShambavi Richard, MD,Prashant Kapoor, MD,Mansi Shah, MD,Ridhi Gupta, MD,Cesar Rodriguez, MD,Harsh Parmar, MD,Gurbakhash Kaur, MD

The second FACE-OFF debate explores whether currently available BCMA bispecific antibodies should be considered a therapeutic class or whether meaningful clinical differences exist among individual agents used to treat relapsed/refractory multiple myeloma (R/R MM).

7 experts are featured in this series

Debate: CAR-T Cell Therapy Versus BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

ByShambavi Richard, MD,Prashant Kapoor, MD,Mansi Shah, MD,Ridhi Gupta, MD,Cesar Rodriguez, MD,Harsh Parmar, MD,Gurbakhash Kaur, MD

The program transitions to the first FACE-OFF debate, where the faculty discuss whether CAR-T cell therapy or BCMA bispecific antibodies should be prioritized as BCMA-directed therapies move into earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM).

7 experts are featured in this series

MAJESTEC-3 Evaluates Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma

ByShambavi Richard, MD,Prashant Kapoor, MD,Mansi Shah, MD,Ridhi Gupta, MD,Cesar Rodriguez, MD,Harsh Parmar, MD,Gurbakhash Kaur, MD

Dr. Harsh Parmar presents results from the phase 3 MAJESTEC-3 trial evaluating the combination of teclistamab and daratumumab versus standard daratumumab-based regimens in patients with relapsed/refractory multiple myeloma (R/R MM) who had received one to three prior lines of therapy.

7 experts are featured in this series

CARTITUDE-4 Supports Earlier CAR-T Use in Relapsed/Refractory Multiple Myeloma

ByShambavi Richard, MD,Prashant Kapoor, MD,Mansi Shah, MD,Ridhi Gupta, MD,Cesar Rodriguez, MD,Harsh Parmar, MD,Gurbakhash Kaur, MD

Dr. Cesar Rodriguez presents findings from the phase 3 CARTITUDE-4 trial, which compared ciltacabtagene autoleucel (cilta-cel) with standard-of-care regimens in patients with relapsed/refractory multiple myeloma (R/R MM) who were refractory to lenalidomide after one to three prior lines of therapy.

9 Experts are featured in this series.

Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community Center

ByAjai Chari, MD,Thomas G. Martin, MD,Jens Hillengass, MD, PhD ,Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ,Louis Williams, MD,Shebli Atrash, MD ,Donna Catamero, ANP-BC, OCN, CCRC,Cesar Rodriguez Valdes, MD ,Shambavi Richard, MD

Panelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.

9 Experts are featured in this series.

Clinical Scenario: A 58-Year Old Woman with Relapsed Refractory Mutiple Myeloma, post-ASCT, MRD-negative, on Bispecific Therapy

ByAjai Chari, MD,Thomas G. Martin, MD,Jens Hillengass, MD, PhD ,Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ,Louis Williams, MD,Shebli Atrash, MD ,Donna Catamero, ANP-BC, OCN, CCRC,Cesar Rodriguez Valdes, MD ,Shambavi Richard, MD

Panelists discuss how to approach treatment decisions and management strategies for a 58-year-old woman with relapsed/refractory multiple myeloma who is post-autologous stem cell transplant, MRD-negative, and currently receiving bispecific antibody therapy, considering factors such as prior treatments, response duration, and long-term treatment goals.

9 Experts are featured in this series.

Dosing Interval and Considerations for Bispecifics Combination in Relapsed Refractory Multiple Myeloma

ByAjai Chari, MD,Thomas G. Martin, MD,Jens Hillengass, MD, PhD ,Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ,Louis Williams, MD,Shebli Atrash, MD ,Donna Catamero, ANP-BC, OCN, CCRC,Cesar Rodriguez Valdes, MD ,Shambavi Richard, MD

Panelists discuss how optimizing dosing intervals and carefully considering combination strategies for bispecific antibodies in relapsed/refractory multiple myeloma could enhance treatment efficacy while managing toxicities and improving patient quality of life.

9 Experts are featured in this series.

Sequencing Therapies in Relapsed Refractory Multiple Myeloma: Bispecifics and CAR T-Cell Therapies

ByAjai Chari, MD,Thomas G. Martin, MD,Jens Hillengass, MD, PhD ,Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ,Louis Williams, MD,Shebli Atrash, MD ,Donna Catamero, ANP-BC, OCN, CCRC,Cesar Rodriguez Valdes, MD ,Shambavi Richard, MD

Panelists discuss how the optimal sequencing of bispecific antibodies and CAR T-cell therapies in relapsed/refractory multiple myeloma could maximize treatment efficacy and improve patient outcomes in this challenging disease setting.

9 Experts are featured in this series.

OPTec: Outpatient Step Up Administration of Teclistamab: Implications in Real-World Practice

ByAjai Chari, MD,Thomas G. Martin, MD,Jens Hillengass, MD, PhD ,Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ,Louis Williams, MD,Shebli Atrash, MD ,Donna Catamero, ANP-BC, OCN, CCRC,Cesar Rodriguez Valdes, MD ,Shambavi Richard, MD

Panelists discuss how the OPTec study, which explores outpatient step-up administration of teclistamab, could impact real-world practice by potentially improving patient convenience and reducing healthcare resource utilization in the treatment of multiple myeloma.

9 Experts are featured in this series.

Prophylactic Tocilizumab in MajesTEC-1 for the Reduction of CRS

ByAjai Chari, MD,Thomas G. Martin, MD,Jens Hillengass, MD, PhD ,Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ,Louis Williams, MD,Shebli Atrash, MD ,Donna Catamero, ANP-BC, OCN, CCRC,Cesar Rodriguez Valdes, MD ,Shambavi Richard, MD

Panelists discuss how prophylactic use of tocilizumab in the MajesTEC-1 trial may reduce the incidence and severity of cytokine release syndrome (CRS) in patients receiving bispecific antibody therapy for multiple myeloma, potentially improving treatment safety and tolerability.

9 Experts are featured in this series.

Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: RedirecTT-1 Follow-Up

ByAjai Chari, MD,Thomas G. Martin, MD,Jens Hillengass, MD, PhD ,Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ,Louis Williams, MD,Shebli Atrash, MD ,Donna Catamero, ANP-BC, OCN, CCRC,Cesar Rodriguez Valdes, MD ,Shambavi Richard, MD

Panelists discuss how the follow-up results from the RedirecTT-1 study provide insights into the long-term efficacy and safety of bispecific antibody combinations in treating relapsed/refractory multiple myeloma, potentially shaping future treatment approaches for this challenging disease.

9 Experts are featured in this series.

Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: TRIMM-2 Study

ByAjai Chari, MD,Thomas G. Martin, MD,Jens Hillengass, MD, PhD ,Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ,Louis Williams, MD,Shebli Atrash, MD ,Donna Catamero, ANP-BC, OCN, CCRC,Cesar Rodriguez Valdes, MD ,Shambavi Richard, MD

Panelists discuss how the TRIMM-2 study explores the potential of combining bispecific antibodies to enhance treatment efficacy in patients with relapsed/refractory multiple myeloma, potentially offering a novel therapeutic strategy for this difficult-to-treat condition.

9 Experts are featured in this series.

Talquetamab, a GPRC5DxCD3 bispecific antibody (BsAb), for Relapsed Refractory Multiple Myeloma: MonumenTAL-1 Data and Implications

ByAjai Chari, MD,Thomas G. Martin, MD,Jens Hillengass, MD, PhD ,Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ,Louis Williams, MD,Shebli Atrash, MD ,Donna Catamero, ANP-BC, OCN, CCRC,Cesar Rodriguez Valdes, MD ,Shambavi Richard, MD

Panelists discuss how Talquetamab, a novel GPRC5DxCD3 bispecific antibody, shows promising results in treating relapsed/refractory multiple myeloma based on the MonumenTAL-1 trial data, potentially offering a new therapeutic option for this challenging patient population.

Latest Updated Articles